William Jl Rieflin

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
South San Francisco, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Mark Meltz, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for William Jl Rieflin

Form 4 holding Director

RAPT Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
36,490
Estimated value
$276,594
Report date
23 May 2024
Price
$7.58
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Lyell Immunopharma, Inc.

Security class
Option (right to buy)
Shares / value
130,000
Estimated value
Report date
14 Jun 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

NGM BIOPHARMACEUTICALS INC

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
05 Apr 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by William Jl Rieflin

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .